Turk Ilac Ve Serum Sanayi Anonim Sirketi

IBSE:TRILC Stock Report

Market Cap: ₺2.8b

Turk Ilac Ve Serum Sanayi Anonim Sirketi Past Earnings Performance

Past criteria checks 2/6

Turk Ilac Ve Serum Sanayi Anonim Sirketi has been growing earnings at an average annual rate of 10.6%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 45.2% per year. Turk Ilac Ve Serum Sanayi Anonim Sirketi's return on equity is 14.7%, and it has net margins of 15.2%.

Key information

10.6%

Earnings growth rate

8.2%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate45.2%
Return on equity14.7%
Net Margin15.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Turk Ilac Ve Serum Sanayi Anonim Sirketi makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

IBSE:TRILC Revenue, expenses and earnings (TRY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,6822561760
30 Jun 241,9461991730
31 Mar 241,615881660
31 Dec 231,9131061590
30 Sep 232,893-2222510
30 Jun 232,383-1392210
31 Mar 232,175-1031930
31 Dec 221,637-821710
30 Sep 2282531940
30 Jun 2281213720
31 Mar 2276037580
31 Dec 2167337400
30 Sep 2155465370
30 Jun 2142686350
31 Mar 2121851270
31 Dec 2020033270
30 Sep 2021952260
31 Dec 1915213210
31 Dec 189714130
31 Dec 17538110

Quality Earnings: TRILC has a high level of non-cash earnings.

Growing Profit Margin: TRILC became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TRILC's earnings have grown by 10.6% per year over the past 5 years.

Accelerating Growth: TRILC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: TRILC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.4%).


Return on Equity

High ROE: TRILC's Return on Equity (14.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 20:10
End of Day Share Price 2025/01/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Turk Ilac Ve Serum Sanayi Anonim Sirketi is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution